Using the Electronic Health Record to Guide Management of Newborn Weight Loss
Beginning With a Healthy Start: A Randomized Controlled Trial of Informatics-Enhanced Newborn Weight Management
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94122
- University of California, San Francisco Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Assignment to a bed assignment on the well newborn service at the time of the first weight measured subsequent to birth weight and at >6 hours and <=96 hours of age
Exclusion Criteria:
- None
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: Newborn Weight Tool (NEWT)
The electronic medical record will display the Newborn Weight Tool along with a banner flagging newborn weight loss greater than or equal to the 75th centile of birth weight
|
The Newborn Weight Tool (NEWT) is publicly available at www.newbornweight.org.
For this intervention, NEWT will be embedded into the electronic medical record along with a flag for weight loss greater than or equal to the 75th centile of birth weight.
Other Names:
|
|
PLACEBO_COMPARATOR: Usual care
As with usual care, the electronic medical record will display the weight only as weight in grams and percent weight lost from birth weight
|
The electronic medical record will display the weight only as weight in grams and percent weight lost from birth weight.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Concordance with feeding recommendation during the birth hospitalization
Time Frame: 0-96 hours
|
Feeding is defined as concordant with feeding recommendation if any of the following occur: 1) for newborns who do not have documented weight loss >=75th NEWT centile, formula is not used; 2) for newborns with only one weight documented that is more pronounced than the 75th centile, no formula is used prior to the weight documented at more pronounced than the 75th centile; 3) for newborns who have two weights documented more pronounced than the 75th centile, formula is used.
|
0-96 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion readmitted to the hospital
Time Frame: 0-30 days
|
Readmission to the hospital after discharge from the birth hospitalization
|
0-30 days
|
|
Length of hospital stay
Time Frame: 0-96 hours
|
Length of stay during the birth hospitalization
|
0-96 hours
|
|
Proportion exclusively breastfed
Time Frame: 0-96 hours
|
Feeding only breast milk without any other fluid or food other than vitamins, minerals and medications
|
0-96 hours
|
|
Proportion with donor milk use
Time Frame: 0-96 hours
|
Use of banked donor milk
|
0-96 hours
|
|
Excess neonatal outpatient utilization
Time Frame: 0-30 days
|
>3 outpatient visits in the first 30 days (newborns may have up to 3 preventive outpatient visits in the first 30 days)
|
0-30 days
|
|
Ratio of indicated formula use to non-indicated formula use during the birth hospitalization
Time Frame: 0-30 days
|
Ratio of formula used either for hypoglycemia or for weight loss >=75th centile to formula used for in the absence of these
|
0-30 days
|
|
Non-preventive outpatient utilization
Time Frame: 0-30 days
|
Number of non-preventive outpatient visits
|
0-30 days
|
|
Outpatient utilization
Time Frame: 0-30 days
|
Number of outpatient visits
|
0-30 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Valerie Flaherman, MD, MPH, Associate Professor of Pediatrics and Epidemiology and Biostatistics
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- 17-23249
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.